Hydromorphone

Generic Name
Hydromorphone
Brand Names
Dilaudid, Exalgo, Hydromorph Contin, Hydromorphone Hp Forte
Drug Type
Small Molecule
Chemical Formula
C17H19NO3
CAS Number
466-99-9
Unique Ingredient Identifier
Q812464R06
Background

Hydromorphone is a pure opioid, a semi-synthetic hydrogenated ketone derivative of morphine that has been available clinically since 1920. Structurally, hydromorphone derived from morphine in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 and 8. Due to these modifications, it present...

Indication

Hydromorphone is indicated for the management of moderate to severe acute pain and severe chronic pain. Due to its addictive potential and overdose risk, hydromorphone is only prescribed when other first-line treatments have failed.
...

Associated Conditions
Neuropathic Pain, Refractory Chronic Cough, Moderate to severe pain
Associated Therapies
-

PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain

Phase 3
Completed
Conditions
Interventions
First Posted Date
2017-12-18
Last Posted Date
2021-03-08
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
214
Registration Number
NCT03375515
Locations
🇨🇳

Rongbo Lin, Fuzhou, Fujian, China

Effect of Tramadol in Prevention of Postpartum Depression

First Posted Date
2017-10-13
Last Posted Date
2019-08-14
Lead Sponsor
Xinqiao Hospital of Chongqing
Target Recruit Count
1230
Registration Number
NCT03309163
Locations
🇨🇳

Xinqiao Hospital, Third Military Medical University, Chongqing, Chongqing, China

Intravenous Lidocaine Randomized Comparative Effectiveness Trial

Phase 4
Completed
Conditions
Interventions
First Posted Date
2017-10-03
Last Posted Date
2020-08-10
Lead Sponsor
Montefiore Medical Center
Target Recruit Count
154
Registration Number
NCT03300674
Locations
🇺🇸

Montefiore Medical Center, Bronx, New York, United States

Epidural and Intravenous Patient-Controlled Analgesia Following Lumbar Spinal Fusion Surgery

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2017-04-14
Last Posted Date
2023-10-26
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
46
Registration Number
NCT03115151
Locations
🇺🇸

University Of Texas Southwestern Medical Center, Zale University Hospital, Dallas, Texas, United States

🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

Acetaminophen IV vs Hydromorphone IV in the ED

Phase 4
Completed
Conditions
Interventions
First Posted Date
2017-04-11
Last Posted Date
2017-11-17
Lead Sponsor
Montefiore Medical Center
Target Recruit Count
220
Registration Number
NCT03107481
Locations
🇺🇸

Montefiore Medical Center, Bronx, New York, United States

The Effectiveness of IV/PO Acetaminophen in the Perioperative Period in Reducing Opiate Use After Lumbar Spine Fusion

First Posted Date
2017-04-07
Last Posted Date
2019-10-08
Lead Sponsor
University of Southern California
Target Recruit Count
28
Registration Number
NCT03104816
Locations
🇺🇸

Keck Hospital of USC, Los Angeles, California, United States

Does IVPCA Increase Opioid Consumption and Side Effects in Fast Track Orthopedic Procedures?

First Posted Date
2016-08-26
Last Posted Date
2016-08-26
Lead Sponsor
Mount Sinai Hospital, Canada
Target Recruit Count
80
Registration Number
NCT02880800
Locations
🇨🇦

Mount Sinai Hospital, Toronto, Ontario, Canada

Pain Medications in Children Undergoing Strabismus Surgery

Not Applicable
Conditions
Interventions
First Posted Date
2016-06-03
Last Posted Date
2016-06-03
Lead Sponsor
St. Louis Children's Hospital
Target Recruit Count
128
Registration Number
NCT02789969
Locations
🇺🇸

St. Louis Children's Hospital, St. Louis, Missouri, United States

© Copyright 2024. All Rights Reserved by MedPath